Breaking News Instant updates and real-time market news.

FPRX

Five Prime

$51.95

-0.54 (-1.03%)

, BMY

Bristol-Myers

$54.66

0.74 (1.37%)

09:06
10/04/16
10/04
09:06
10/04/16
09:06

Five Prime advances into Phase 1b portion of combination trial

Five Prime Therapeutics (FPRX) announced that it has initiated the Phase 1b portion of the clinical trial evaluating the immunotherapy combination of cabiralizumab, Five Prime's investigational monoclonal antibody that inhibits colony stimulating factor-1 receptor, with OPDIVO, Bristol-Myers Squibb's (BMY) PD-1 immune checkpoint inhibitor, in multiple tumor types. Five Prime initiated the Phase 1a/1b trial, which is expected to enroll approximately 280 patients, in September 2015. During Phase 1a, Five Prime evaluated the safety, pharmacokinetics and biomarkers of escalating doses of cabiralizumab as a monotherapy, as well as in combination with the approved 3 mg/kg dose of nivolumab. Five Prime will continue to run the Phase 1b portion of the trial and will evaluate the safety, tolerability and preliminary efficacy of the selected dose of cabiralizumab in combination with nivolumab for the treatment of advanced solid tumors, including but not limited to non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, glioblastoma, renal cell carcinoma and ovarian cancer.

FPRX

Five Prime

$51.95

-0.54 (-1.03%)

BMY

Bristol-Myers

$54.66

0.74 (1.37%)

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

FPRX Five Prime
$51.95

-0.54 (-1.03%)

01/20/16
FBCO
01/20/16
INITIATION
Target $54
FBCO
Outperform
Five Prime initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kennen MacKay started Five Prime Therapeutics with an Outperform rating and $54 price target.
01/21/16
01/21/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3M (MMM) initiated with a Buy at Citi... AMAG Pharmaceuticals (AMAG) initiated with an Equal Weight at Barclays... Acceleron (XLRN) initiated with an Outperform at Credit Suisse... Agios Pharmaceuticals (AGIO) initiated with an Outperform at Credit Suisse... Akebia (AKBA) initiated with a Neutral at Credit Suisse... CIT Group (CIT) initiated with a Hold at Deutsche Bank... Check Point (CHKP) initiated with a Neutral at Cleveland Research... Clovis (CLVS) initiated with an Outperform at Credit Suisse... Colfax (CFX) initiated with a Sell at Citi... Danaher (DHR) initiated with a Neutral at Citi... Dover (DOV) initiated with a Neutral at Citi... Emerson (EMR) initiated with a Sell at Citi... Endo (ENDP) initiated with an Equal Weight at Barclays... Endocyte (ECYT) initiated with an Outperform at Credit Suisse... FibroGen (FGEN) initiated with a Neutral at Credit Suisse... FireEye (FEYE) initiated with an Outperform at Northland... Five Prime (FPRX) initiated with an Outperform at Credit Suisse... Flowserve (FLS) initiated with a Neutral at Citi... General Electric (GE) initiated with a Buy at Citi... Honeywell (HON) initiated with a Buy at Citi... Ignyta (RXDX) initiated with an Outperform at Credit Suisse... Illinois Tool Works (ITW) initiated with a Buy at Citi... Imperva (IMPV) initiated with an Outperform at Northland... Ingersoll-Rand (IR) initiated with a Buy at Citi... Joint Corp. (JYNT) initiated with a Buy at Maxim... M&T Bank (MTB) resumed with a Neutral at JPMorgan... Medivation (MDVN) initiated with an Outperform at Credit Suisse... Newfield Exploration (NFX) initiated with an Outperform at Imperial Capital... OvaScience (OVAS) initiated with an Underperform at Credit Suisse... PFSweb (PFSW) initiated with a Buy at Canaccord... Palo Alto (PANW) initiated with an Outperform at Northland... Perrigo (PRGO) initiated with an Overweight at Barclays... Prothena (PRTA) initiated with an Outperform at Credit Suisse... Puma Biotechnology (PBYI) initiated with an Outperform at Credit Suisse... Rockwell Automation (ROK) initiated with a Neutral at Citi... Seattle Genetics (SGEN) initiated with an Outperform at Credit Suisse... Shopify (SHOP) initiated with an Outperform at Wedbush... Square (SQ) initiated with a Market Perform at William Blair... TESARO (TSRO) initiated with an Outperform at Wedbush... Tyco (TYC) initiated with a Neutral at Citi... Ultragenyx (RARE) initiated with an Outperform at Credit Suisse.
05/11/16
05/11/16
NO CHANGE

Leerink major pharma & biotech analyst holds analyst/industry conference call
Biotech Analyst Schmidt and Major Pharmaceuticals Analyst Fernandez, along with University of Chicago Departments of Pathology & Medicine, Professor Dr. Thomas F. Gajewski, discuss the tumor micro-environment on an Analyst/Industry conference call to be held on May 11 at 2 pm.
08/09/16
WELS
08/09/16
NO CHANGE
WELS
Five Prime weakness overdone, says Wells Fargo
After a trial of the OPDIVO cancer treatment of Five Prime's (FPRX) partner, Bristol Myers Squibb (BMY), showed disappointing results, Wells Fargo thinks that the nearly 9% decline in Five Prime's stock was overdone. The firm thinks that it's "premature" to determine that Merck's (MRK) Keytruda has overtaken OPDIVO. The firm believes that Five Prime's OPDIVO can redeem itself in upcoming studies, and it thinks that Five Prime's stock can advance if the actor-1 receptor is proven to be a worthwhile target ,whether or not OPDIVO is shown to be effective. The firm keeps an Outperform rating on Five Prime.
BMY Bristol-Myers
$54.66

0.74 (1.37%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

NFX

Newfield Exploration

$28.45

0.89 (3.23%)

11:45
06/29/17
06/29
11:45
06/29/17
11:45
Options
Newfield Exploration call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

XLK

Technology Select Sector SPDR

$54.81

-0.96 (-1.72%)

, XLF

Financial Select Sector

$24.79

0.27 (1.10%)

11:38
06/29/17
06/29
11:38
06/29/17
11:38
Technical Analysis
Technical View: S&P 500 breaks 2420, bounces fractionally »

The S&P 500 (SPX)…

XLK

Technology Select Sector SPDR

$54.81

-0.96 (-1.72%)

XLF

Financial Select Sector

$24.79

0.27 (1.10%)

SPY

SPDR S&P 500 ETF Trust

$241.95

-1.54 (-0.63%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$91.56

1.7362 (1.93%)

11:30
06/29/17
06/29
11:30
06/29/17
11:30
Options
Bullish option play in JP Morgan as shares rally »

Bullish option play in JP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

11:25
06/29/17
06/29
11:25
06/29/17
11:25
General news
Treasury announced a $72 B 3- and 6-month bill auction for Monday »

Treasury announced a $72…

INFO

IHS Markit

$45.05

-0.32 (-0.71%)

11:25
06/29/17
06/29
11:25
06/29/17
11:25
Conference/Events
The National Economists Club to hold a luncheon meeting Symbol changed to INFO IHS Markit »

National Economists Club…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

QVCA

QVC Group

$24.61

0.1 (0.41%)

, QVCB

QVC Group

11:25
06/29/17
06/29
11:25
06/29/17
11:25
Conference/Events
FBN Securities media analyst to hold a luncheon meeting »

Media Analyst Routh…

QVCA

QVC Group

$24.61

0.1 (0.41%)

QVCB

QVC Group

LVNTA

Liberty Ventures

$52.69

1.21 (2.35%)

GNCMA

General Communications

$36.81

0.97 (2.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 10

    Jul

ALRN

Aileron Therapeutics

11:23
06/29/17
06/29
11:23
06/29/17
11:23
Syndicate
Breaking Syndicate news story on Aileron Therapeutics »

Aileron Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

SHLD

Sears

$8.01

0.29 (3.76%)

11:22
06/29/17
06/29
11:22
06/29/17
11:22
Hot Stocks
Breaking Hot Stocks news story on Sears »

Returning to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$8.01

0.29 (3.76%)

11:20
06/29/17
06/29
11:20
06/29/17
11:20
Hot Stocks
Breaking Hot Stocks news story on Sears »

Berkowitz says Fairholme…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$72.91

-0.01 (-0.01%)

11:20
06/29/17
06/29
11:20
06/29/17
11:20
Options
Abbvie attracts an opening call write »

Abbvie attracts an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$8.01

0.29 (3.76%)

11:17
06/29/17
06/29
11:17
06/29/17
11:17
Hot Stocks
Real estate value the 'margin of safety' in Sears investment, Berkowitz says »

Bruce Berkowitz,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
06/29/17
06/29
11:17
06/29/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$8.01

0.29 (3.76%)

11:16
06/29/17
06/29
11:16
06/29/17
11:16
Hot Stocks
Berkowitz sees Sears net asset value at $90 per share »

Bruce Berkowitz of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
06/29/17
06/29
11:16
06/29/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$961.01

12.92 (1.36%)

11:14
06/29/17
06/29
11:14
06/29/17
11:14
Technical Analysis
Technical View: Alphabet Class A has an active bearish pattern »

A bearish head and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$1.87

0.039 (2.13%)

11:13
06/29/17
06/29
11:13
06/29/17
11:13
Hot Stocks
Bombardier says Transportation restructuring costs included in previous guidance »

As part of the global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:11
06/29/17
06/29
11:11
06/29/17
11:11
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

11:11
06/29/17
06/29
11:11
06/29/17
11:11
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

11:11
06/29/17
06/29
11:11
06/29/17
11:11
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

DBD

Diebold

$27.88

0.425 (1.55%)

11:11
06/29/17
06/29
11:11
06/29/17
11:11
Hot Stocks
CMA says Diebold sale resolves concerns over cashpoint merger »

After the Competition and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHTR

Charter

$340.30

10.43 (3.16%)

11:10
06/29/17
06/29
11:10
06/29/17
11:10
Options
Renewed call buying in Charter »

Renewed call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

JCOM

j2 Global

$87.08

0.83 (0.96%)

, TWTR

Twitter

$17.74

-0.2132 (-1.19%)

11:06
06/29/17
06/29
11:06
06/29/17
11:06
Hot Stocks
IGN, Twitter partner for global live stream of San Diego Comic-Con »

J2 Global's (JCOM)…

JCOM

j2 Global

$87.08

0.83 (0.96%)

TWTR

Twitter

$17.74

-0.2132 (-1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 28

    Sep

CY

Cypress Semiconductor

$14.35

1.15 (8.71%)

, ARW

Arrow Electronics

$79.00

-0.48 (-0.60%)

11:02
06/29/17
06/29
11:02
06/29/17
11:02
Hot Stocks
Cypress Semiconductor, Arrow Electronics announce IoT development platform »

Cypress Semiconductor…

CY

Cypress Semiconductor

$14.35

1.15 (8.71%)

ARW

Arrow Electronics

$79.00

-0.48 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 07

    Sep

PCYO

Pure Cycle

$7.50

-0.05 (-0.66%)

, KBH

KB Home

$23.57

-0.49 (-2.04%)

11:00
06/29/17
06/29
11:00
06/29/17
11:00
Hot Stocks
Pure Cycle to sell lots at Sky Ranch property to KB Home, Taylor Morrison »

Pure Cycle (PCYO)…

PCYO

Pure Cycle

$7.50

-0.05 (-0.66%)

KBH

KB Home

$23.57

-0.49 (-2.04%)

TMHC

Taylor Morrison

$23.91

-0.32 (-1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$34.08

-0.27 (-0.79%)

11:00
06/29/17
06/29
11:00
06/29/17
11:00
Options
AstraZeneca attracts a defensive option play »

AstraZeneca attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.